Corvus Pharmaceuticals CRVS Issuances of common stock from employee benefit plans receivable
Issuances of common stock from employee benefit plans receivable at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ConversionOfStockAmountIssued1.
The official record: Corvus Pharmaceuticals’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's issuances of common stock from employee benefit plans receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's issuances of common stock from employee benefit plans receivable?
- Corvus Pharmaceuticals (CRVS) reported issuances of common stock from employee benefit plans receivable of $442.25K in Q4 2025.
- How has Corvus Pharmaceuticals's issuances of common stock from employee benefit plans receivable changed year-over-year?
- Corvus Pharmaceuticals's issuances of common stock from employee benefit plans receivable decreased by 86.8% year-over-year, from $3.35M to $442.25K.
- What does issuances of common stock from employee benefit plans receivable mean?
- This represents the value of common stock issued through the conversion of debt, preferred stock, or other equity-linked instruments. It highlights the shift in capital structure from liabilities or hybrid securities into common equity. Investors track this to assess the impact of balance sheet restructuring on share count and shareholder dilution.